Key Drivers
- Strong cash conversion
- Heavy debt load
- Moderate valuation
AIAI Summary
COLL now looks less like a stable specialty-pharma cash cow and more like a levered ADHD growth bet after AZSTARYS, so the investment case hinges on management using strong free cash flow to scale the franchise without worsening debt risk or missing integration targets.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash conversion
- •Heavy debt load
- •Moderate valuation
COLL shows strong margins and cash generation, but its high leverage, moderate interest coverage, and only fair valuation keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights:
- •Support held
- •Breakout failed
- •Range still capped
Over the last month, COLL looks flat-to-down overall: buyers defended the low-32s and sparked a rally to $39.33, but the quick reversal to $33.78 signals a failed breakout and limits upside until the mid-$35 area is reclaimed.
Rally to $39.33 quickly reversed to $33.78, signaling a failed breakout and sharp short-term volatility
Sentiment & News
Key News Insights:
- •Earnings Beat
- •AZSTARYS Deal
- •Guidance Raised
Collegium beat Q1 estimates, posted solid revenue growth, completed the AZSTARYS acquisition, and raised 2026 guidance, signaling a stronger growth outlook ahead.
The combination of a strong quarter and a strategic acquisition should support sentiment by expanding Collegium's revenue base and long-term earnings potential
Similar Companies in Healthcare
Other companies in the same sector with AI ratings